DexCom, Inc.
DXCM Real Time Price USD$DXCM is featured in our Tina Smith strategy.
All StrategiesRecent trades of DXCM by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in DXCM holdings by institutional investors
Quarterly net insider trading by DXCM's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$370,000 Jul 20, 2026 Issue: Medicare/Medicaid Trade (domestic/foreign) Health Issues
-
$380,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$390,000 Jan 20, 2026 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid
-
$370,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$290,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$270,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$260,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$130,000 Oct 21, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
-
$170,000 Sep 06, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
-
$160,000 Sep 06, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
-
$56,500 Jan 03, 2024 Issue: Medicare/Medicaid Health Issues
-
$56,500 Oct 19, 2023 Issue: None
-
$67,450 Jul 12, 2023 Issue: Medicare/Medicaid
-
$62,000 Jan 10, 2023 Issue: Health Issues
-
$56,500 Oct 12, 2022 Issue: Economics/Economic Development Medicare/Medicaid
-
$57,000 Jul 12, 2022 Issue: Health Issues
-
$57,000 May 05, 2022 Issue: Medicare/Medicaid Health Issues
-
$57,000 Mar 23, 2022 Issue: Medicare/Medicaid Health Issues
-
$57,000 Oct 05, 2021 Issue: None
-
$57,000 Jul 02, 2021 Issue: None
-
$58,600 Apr 14, 2021 Issue: None
-
$56,274 Jan 08, 2021 Issue: HEALTH ISSUES
-
$57,250 Oct 19, 2020 Issue: MEDICARE/MEDICAID
-
$58,600 Jul 13, 2020 Issue: MEDICARE/MEDICAID
-
$58,632 Apr 13, 2020 Issue: None
-
$57,250 Jan 10, 2020 Issue: None
-
$56,274 Oct 08, 2019 Issue: Health Issues Medicare/Medicaid
-
$52,675 Jul 12, 2019 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 22, 2019 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 19, 2018 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 20, 2018 Issue: Medicare/Medicaid Health Issues
-
$180,000 Jul 20, 2018 Issue: Medicare/Medicaid Health Issues
-
$250,000 Apr 19, 2018 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 19, 2018 Issue: Medicare/Medicaid Health Issues
-
$7,651 Jan 16, 2018 Issue: Health Issues Medicare/Medicaid
-
$9,700 Oct 23, 2017 Issue: Medicare/Medicaid
-
$6,750 Jul 21, 2017 Issue: Health Issues
-
$8,375 Jul 21, 2017 Issue: Health Issues
-
$80,000 Jul 18, 2017 Issue: Medicare/Medicaid Health Issues
-
$130,000 Apr 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$25,650 Jan 23, 2017 Issue: Health Issues
-
$120,000 Jan 23, 2017 Issue: Medicare/Medicaid Health Issues
-
$12,750 Oct 20, 2016 Issue: Health Issues
-
$150,000 Oct 17, 2016 Issue: Medicare/Medicaid Health Issues
-
$130,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues
-
$36,000 Jul 20, 2016 Issue: Health Issues
-
$36,000 Apr 20, 2016 Issue: Health Issues
-
$20,000 Apr 19, 2016 Issue: Health Issues
-
$70,000 Jan 15, 2016 Issue: Health Issues
-
$70,000 Oct 14, 2015 Issue: Health Issues
-
$60,000 Jul 16, 2015 Issue: Health Issues
-
$50,000 Apr 18, 2015 Issue: Health Issues
-
$20,000 Jan 18, 2015 Issue: Health Issues
-
$40,000 Oct 16, 2014 Issue: Health Issues
-
$60,000 Jul 17, 2014 Issue: Health Issues
-
$20,000 Apr 20, 2014 Issue: Health Issues
-
$40,000 Aug 12, 2007 Issue: Health Issues
-
$100,000 Feb 09, 2007 Issue: Health Issues
Former government officials who have lobbied for DXCM
10 former government officials from 6 congressional offices at 2 lobbying firms have lobbied for DXCM, most recently Jul 20, 2026.
-
John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
-
Charlie Chapman House Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee
-
Chris Kelly Senate Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn -
Jeff Mackinnon House LD & LA Rep. Joe Barton (RTexas) -
Jeffery Mortier House Prof Staff on E&C Cmte LA Rep Whitfield and Intern Devin Nunes -
Sarah Walter Senate Former Legislative Director/Chief Counsel, Sen. John Breaux -
Edward Whitfield House U.S. Representative (21 yrs.)
-
Dylan Moore House Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10)
DXCM Estimated quarterly lobbying spending
DXCM Revenue by Segment or Geography
New DXCM patent grants
-
Patent Title: Display screen or portion thereof with graphical user interface for analyte data presentation Feb. 21, 2023
-
Patent Title: Display screen or portion thereof with graphical user interface for analyte data presentation Feb. 21, 2023
-
Patent Title: Data backfilling for continuous glucose monitoring Jun. 12, 2018
-
Patent Title: Oxygen enhancing membrane systems for implantable devices Jun. 12, 2018
-
Patent Title: Analyte sensor Jun. 05, 2018
-
Patent Title: Remote monitoring of analyte measurements May. 29, 2018
-
Patent Title: Systems and methods for processing and transmitting sensor data May. 22, 2018
-
Patent Title: End of life detection for analyte sensors May. 22, 2018
-
Patent Title: System and method for providing alerts optimized for a user May. 22, 2018
-
Patent Title: Systems and methods for a continuous monitoring of analyte values May. 22, 2018
-
Patent Title: Systems and methods for a continuous monitoring of analyte values May. 22, 2018
-
Patent Title: Systems and methods for processing and transmitting sensor data May. 15, 2018
-
Patent Title: Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device May. 08, 2018
-
Patent Title: Remote monitoring of analyte measurements May. 08, 2018
-
Patent Title: Adaptive interface for continuous monitoring devices Apr. 24, 2018
-
Patent Title: Adaptive interface for continuous monitoring devices Apr. 10, 2018
-
Patent Title: Integrated delivery device for continuous glucose sensor Apr. 10, 2018
-
Patent Title: Zwitterion surface modifications for continuous sensors Apr. 10, 2018
-
Patent Title: Device and method for determining analyte levels Apr. 03, 2018
-
Patent Title: Transcutaneous analyte sensors, applicators therefor, and associated methods Apr. 03, 2018
-
Patent Title: Systems and methods for processing and transmitting sensor data Apr. 03, 2018
-
Patent Title: Systems and methods for processing and transmitting sensor data Apr. 03, 2018
-
Patent Title: System and methods for processing analyte sensor data for sensor calibration Mar. 20, 2018
-
Patent Title: Analyte sensor Mar. 06, 2018
-
Patent Title: Systems and methods for processing sensor data Feb. 27, 2018
-
Patent Title: Systems and methods for a continuous monitoring of analyte values Feb. 27, 2018
-
Patent Title: System and methods for processing analyte sensor data Feb. 20, 2018
-
Patent Title: Remote monitoring of analyte measurements Jan. 02, 2018
-
Patent Title: Advanced analyte sensor calibration and error detection Dec. 26, 2017
-
Patent Title: Adaptive interface for continuous monitoring devices Dec. 19, 2017
-
Patent Title: Sensors for continuous analyte monitoring, and related methods Dec. 19, 2017
-
Patent Title: Systems and methods for processing sensor data Dec. 12, 2017
-
Patent Title: Remote monitoring of analyte measurements Dec. 12, 2017
-
Patent Title: Receivers for analyzing and displaying sensor data Dec. 05, 2017
-
Patent Title: Transcutaneous analyte sensor Dec. 05, 2017
-
Patent Title: Transcutaneous analyte sensor Dec. 05, 2017
-
Patent Title: Integrated insulin delivery system with continuous glucose sensor Nov. 28, 2017
-
Patent Title: Transcutaneous analyte sensor Nov. 14, 2017
-
Patent Title: Advanced analyte sensor calibration and error detection Nov. 07, 2017
-
Patent Title: Sensor head for use with implantable devices Oct. 31, 2017
-
Patent Title: Advanced analyte sensor calibration and error detection Oct. 31, 2017
-
Patent Title: Techniques to improve polyurethane membranes for implantable glucose sensors Oct. 31, 2017
-
Patent Title: Transcutaneous analyte sensor Oct. 31, 2017
-
Patent Title: Remote monitoring of analyte measurements Oct. 31, 2017
-
Patent Title: Analyte sensing biointerface Oct. 17, 2017
-
Patent Title: Zwitterion surface modifications for continuous sensors Oct. 17, 2017
-
Patent Title: Systems and methods for processing and transmitting sensor data Oct. 10, 2017
-
Patent Title: Dual electrode system for a continuous analyte sensor Jan. 07, 2014
-
Patent Title: Electrode systems for electrochemical sensors May. 22, 2012
-
Patent Title: Dual electrode system for a continuous analyte sensor Dec. 20, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded to DXCM from public contracts
Recent insights relating to DXCM
Recent picks made for DXCM stock on CNBC
ETFs with the largest estimated holdings in DXCM
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DXCM stock a Buy, Sell, or Hold?
- What is the price target for $DXCM stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DXCM stock?
- Who owns the most shares of $DXCM stock?
- What funds own $DXCM stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DXCM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
- Address San Diego, CA
- Market Cap 32.0 billion
- Employees 11,100
- Industrial Classification Surgical & Medical Instruments & Apparatus
We estimate that -- received a compensation of -- in --, making them the highest paid executive at DXCM, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|